FLT3 and acute myeloid leukemia: In de novo AML, constitutive activation of STATs can be achieved by auto- and paracrine factors such as IL-6, decreased expression of negative regulators such as SOCS1 or activating mutations in other (non-JAK) upstream kinases such as FMS-like tyrosine kinase 3 (FLT3) [86].